posted 11/01/02
Among women at high risk for
type 2 diabetes, beginning treatment before they actually develop the disease
can preserve the health of their insulin-producing cells and stave off diabetes,
That, according to research
presented at the ADA 62nd Scientific Session.
"The study has important implications for treatment strategies to prevent type 2
diabetes. It also helps define the primary cause of the disease: the failure of
insulin-secreting cells caused by high insulin demands when the body's tissues
become resistant to its own insulin," said Thomas A. Buchanan, M.D., of Keck
School of Medicine, University of California.
The Troglitazone in Prevention of Diabetes (TRIPOD) study previously found that
using a drug to lessen insulin resistance could reduce the demands on beta
cells, which produce insulin in response to glucose, and prevent or slow type 2
diabetes onset in Latinas with recent gestational diabetes.
Although gestational diabetes usually disappears after childbirth, patients
commonly remain resistant to their own insulin and 30 percent to 50 percent
develop type 2 diabetes within a few years after pregnancy, Buchanan said. These
women are considered at high risk for developing diabetes.
The researchers randomly assigned 121 young Latinas with recent gestational
diabetes a daily dose of either troglitazone or a placebo. At that time,
physicians nationwide commonly prescribed troglitazone to treat type 2 diabetes,
because it helps the body's cells more effectively use insulin to absorb
glucose. The Food and Drug Administration recalled troglitazone in 2000, and the
researchers switched to prescribing pioglitazone, a similar-acting drug, in the
ongoing study.
During the more than four years in which women were monitored, the group of 56
women who took the drug from the very start saw their insulin sensitivity and
glucose tolerance tests remain stable. But among the 65 women who started on
placebo, insulin sensitivity fell by 25 percent and acute insulin response fell
by 39 percent. Glucose tolerance test levels rose by 10 percent, indicating
growing levels of sugar in the blood.
When the researchers looked specifically at the group of women who originally
received placebo, but were switched to troglitazone upon developing diabetes,
they found that those women had an average decline in beta-cell function of 30
percent during the time they were developing diabetes while taking placebo. Once
they developed diabetes and started taking the drug, the beta-cell decline
stopped.
Here is how it works: When the body's muscle and fat cells grow resistant to
insulin, the beta cells in the pancreas shift into overdrive to produce more
insulin to compensate. Over time, this high workload causes beta cells to wear
out in some people and produce less insulin, or stop altogether, causing type 2
diabetes. Buchanan and colleagues believe that lessening the workload might keep
the beta cells from failing, thereby preventing diabetes.
The results from this new analysis indicate that intervening early, before
diabetes develops, saves about 30 percent more beta cells than can be saved if
treatment is withheld until diabetes first develops.
The researchers are now seeking to understand why some peoples' beta cells wear
out under high workloads, while others' do not.
Source: Diabetes In Control Dot Com.
Home - Table of Contents - Donate Now - About Diabetes - Warning Signs - Complications - Screening Test - Diabetes Terms - Site Search - Meet Mr. Diabetes® - Wake Up And Walk® Tour - Latest News - Headlines & News Stories - Health & Fitness - About Us - FAQ - Research Form - - Message Board - Privacy Policy - Legal Notices - How to Contact Us - Comments form - Suggestion Form - Our E-Mail Addresses - Our Address and Phone Numbers - Links - Contact Us